The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway ; volume:15 ; number:1 ; day:14 ; month:2 ; year:2015 ; pages:1-11 ; date:12.2015
BMC cancer ; 15, Heft 1 (14.2.2015), 1-11, 12.2015
- Creator
-
Wilson, Caroline
- Contributor
-
Ottewell, Penelope
Coleman, Robert E.
Holen, Ingunn
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1066-7
- URN
-
urn:nbn:de:1111-2016110619827
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wilson, Caroline
- Ottewell, Penelope
- Coleman, Robert E.
- Holen, Ingunn
- SpringerLink (Online service)
Other Objects (12)
Acid affairs in anti-tumour immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
The nuclear factor ID3 endows macrophages with a potent anti-tumour activity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
Ruthenacarborane complexes as building blocks for the design of novel anti-tumour agents
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity
Acid affairs in anti-tumour immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
The nuclear factor ID3 endows macrophages with a potent anti-tumour activity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
Ruthenacarborane complexes as building blocks for the design of novel anti-tumour agents
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity
Acid affairs in anti-tumour immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
The nuclear factor ID3 endows macrophages with a potent anti-tumour activity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
Ruthenacarborane complexes as building blocks for the design of novel anti-tumour agents
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells